Lower risk of hypoglycaemia and greater odds for weight loss with initiation of insulin detemir compared with insulin glargine in Turkish patients with type 2 diabetes mellitus: local results of a multinational observational study

[1] Hirsch IB(2013)Standards of medical care in diabetes--2013 Diabetes Care 36 S11-S66

[2] Poon K(2005)Intensifying insulin therapy in patients with type 2 diabetes mellitus Am J Med 118 21S-26S

[3] King AB(2010)Glargine and detemir: Safety and efficacy profiles of the long-acting basal insulin analogs Drug Healthc Patient Saf 2 213-223

[4] Jakobsen M(2012)Insulin analogues dosing and costs - comparing real-life daily doses of insulin detemir and insulin glargine in type 2 diabetes patients BMC Endocr Disord 12 21-216

[5] Dalsgaard M(2011)First insulinization with basal insulin in patients with Type 2 diabetes in a real-world setting in Asia J Diabetes 3 208-1618

[6] Hormann M(2010)A comparison of intermediate and long-acting insulins in people with type 2 diabetes starting insulin: an observational database study Int J Clin Pract 64 1609-208

[7] Moller DV(2008)Guidelines for good pharmacoepidemiology practices (GPP) Pharmacoepidemiol Drug Saf 17 200-661

[8] Tsai ST(2012)Study of Once Daily Levemir (SOLVE): insights into the timing of insulin initiation in people with poorly controlled type 2 diabetes in routine clinical practice Diabetes Obes Metab 14 654-1136

[9] Pathan F(2012)The safety and efficacy of adding once-daily insulin detemir to oral hypoglycaemic agents in patients with type 2 diabetes in a clinical practice setting in 10 countries Diabetes Obes Metab 14 1129-470

[10] Ji L(2013)Effect of baseline HBA1C on glycemic control and diabetes management following initiation of once-daily insulin detemir in real-life clinical practice Endocr Pract 19 462-321

[1] Hirsch IB(2013)Standards of medical care in diabetes--2013 Diabetes Care 36 S11-S66

[2] Poon K(2005)Intensifying insulin therapy in patients with type 2 diabetes mellitus Am J Med 118 21S-26S

[3] King AB(2010)Glargine and detemir: Safety and efficacy profiles of the long-acting basal insulin analogs Drug Healthc Patient Saf 2 213-223

[4] Jakobsen M(2012)Insulin analogues dosing and costs - comparing real-life daily doses of insulin detemir and insulin glargine in type 2 diabetes patients BMC Endocr Disord 12 21-216

[5] Dalsgaard M(2011)First insulinization with basal insulin in patients with Type 2 diabetes in a real-world setting in Asia J Diabetes 3 208-1618

[6] Hormann M(2010)A comparison of intermediate and long-acting insulins in people with type 2 diabetes starting insulin: an observational database study Int J Clin Pract 64 1609-208

[7] Moller DV(2008)Guidelines for good pharmacoepidemiology practices (GPP) Pharmacoepidemiol Drug Saf 17 200-661

[8] Tsai ST(2012)Study of Once Daily Levemir (SOLVE): insights into the timing of insulin initiation in people with poorly controlled type 2 diabetes in routine clinical practice Diabetes Obes Metab 14 654-1136

[9] Pathan F(2012)The safety and efficacy of adding once-daily insulin detemir to oral hypoglycaemic agents in patients with type 2 diabetes in a clinical practice setting in 10 countries Diabetes Obes Metab 14 1129-470

[10] Ji L(2013)Effect of baseline HBA1C on glycemic control and diabetes management following initiation of once-daily insulin detemir in real-life clinical practice Endocr Pract 19 462-321